PTEN and breast carcinoma: In a study with 547 human breast cancer patient samples and 41 established cell lines, the mutational status of PIK3CA, AKT and PTEN were analyzed as well as the effects of pathway mutations on the sensitivity to PI3K inhibitor LY294002 [140].